Indexes
Currency / Forex
Commodities
Market News
MARKET SNAPSHOT: U.S. Stocks Trim Gains As Financial Shares Turn Negative
Top / Flop
38,96+7.37%
30,62+5.26%
47,18+4.31%
24,04+3.40%
25,18-4.44%
2,63-5.05%
42,90-6.90%
61,38-18.06%
Headlines
Thursday, 22 February
U.S. jobless claims near 45-year low as economic outlook brightens
3h ago - WASHINGTON (Reuters) - The number of Americans filing for unemployment benefits fell to a near 45-year low last week, pointing to strong job growth in February and solid momentum in the economy.
German court delays ruling on diesel ban to next week
1h ago - LEIPZIG, Germany (Reuters) - A German court has delayed a ruling on whether major cities can ban heavily polluting diesel cars, which could hit the resale value of up to 15 million vehicles in Europe's largest car market and force automakers to pay for costly modifications.
BAT progress on sales and next-generation devices hit shares
6h ago - LONDON (Reuters) - British American Tobacco's (>> British American Tobacco) weaker than expected 2017 sales growth and progress on next-generation products combined to send its share price down as much as nearly 5 percent on Thursday to an 18-month low.
ECB rejected even token change in policy message at Jan meeting -minutes
5h ago - FRANKFURT (Reuters) - European Central Bank policymakers meeting last month rejected even a token change in the bank's policy message, arguing that it was premature to signal policy normalisation given weak inflation, the minutes of the meeting showed on Thursday.
Amazon Is Taking Over the Stock Market, Too -- 2nd Update
20h ago - By Akane Otani Three technology titans have powered nearly half of the S&P 500's advance this year, a worrying sign for investors...
Deutsche Telekom Swings to Profit in 4Q
13h ago - By Marc Navarro Gonzalez Deutsche Telekom AG said Thursday that it returned to profit in the fourth quarter of 2017, largely boosted by...
Sangamo in $3 billion gene-editing deal with Gilead
4h ago - (Reuters) - U.S. drugmaker Gilead Sciences Inc (>> Gilead Sciences) will use Sangamo Therapeutics Inc's (>> Sangamo Therapeutics Inc) gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion (2.16 billion pounds) to Sangamo, the companies said on Thursday.
More news